Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

Giuseppe Aprile¹
Francesco Leone²,³
Riccardo Giampieri²,³
Mariaelena Casagrande¹
Donatella Marino²,³
Luca Faloppi⁴
Stefano Casinu⁴
Gianpiero Fasola¹
Mario Scartozzi⁵,⁶

¹Department of Oncology, University and General Hospital, Udine, Italy;
²Medical Oncology Department, University of Turin, Institute for Cancer Research and Treatment, Candliolo, Turin, Italy;
³Medical Oncology Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy;
⁴Medical Oncology Department, University of Cagliari, Cagliari, Italy;
⁵General Hospital, Cagliari, Italy

Abstract: The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 15–17) is the world-class conference co-sponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, the American Gastroenterological Association Institute, and the Society of Surgical Oncology, in which the most innovative research results in digestive tract oncology are presented and discussed. In its twelfth edition, the meeting has provided new insights focusing on the underpinning biology and clinical management of gastrointestinal malignancies. More than 3,400 health care professionals gathered from all over the world to share their experiences on how to bridge the recent novelties in cancer biology with everyday medical practice. In this article, the authors report on the most significant advances, didactically moving on three different anatomic tracks: gastrointestinal malignancies, pancreatic and biliary cancers, and colorectal adenocarcinomas.

Keywords: colorectal cancer, gastric cancer, ramucirumab, pembrolizumab, target therapy, onartuzumab, AMG 337

Introduction

Significant studies have been presented at the 2015 Gastrointestinal Cancers Symposium, an outstanding appointment that is held every January in San Francisco, CA, USA. Although this year the practice-changing results were limited, results of many studies have markedly contributed to the expansion of our knowledge in the biology of gastrointestinal malignancies and to fine-tune the available treatment options.

Aims of this report are to recall and comment on the most significant preclinical and clinical studies that have been presented at the scientific venue, which will continue the major progress made in the past decades.¹ In the gastroesophageal track, we will present and reason on the available results of the studies testing mesenchymal epithelial transition (MET) factor inhibitors (AMG 337 and onartuzumab) and programmed cell death receptor 1 ligand (PD-L1) inhibitors (pembrolizumab) in patients with upper gastrointestinal tract diseases. In the second section of the manuscript, we will describe how a comprehensive molecular profiling of biliary tract cancers may be used as a tool for treatment and prognostic stratification, update on the method for refining optimal candidates for sorafenib in hepatocellular carcinoma (HCC), and discuss how to expand valuable treatment options in pancreatic carcinomas, including the novel MM-398 and PF-04136309. In the final section focused on colorectal cancers (CRCs), we will face the most recent advances in molecular selection for targeted therapies and understand that CRC has many underlying drivers, as well as the opportunity to identify targets responsible for drug resistance and the possibility of reshaping the


**Table 1** Significant clinical trials presented at the Gastrointestinal Cancers Symposium 2015 investigating novel agents in gastric, liver, and colorectal carcinomas

| Authors            | Phase | Treatment line | Design                        | Primary end point | Trial outcome               |
|--------------------|-------|----------------|-------------------------------|-------------------|----------------------------|
| Kwak et al<sup>7</sup> | I     | Refractory     | AMG 337, single arm           | Safety            | Good tolerance, RR: 62%    |
| Shah et al<sup>6</sup> | II, randomized | First-line | FOLFIRI + onartuzumab         | OS                | HR: 0.67; (95% CI: 0.51–0.90; $P=0.0059$) |
| Zhu et al<sup>12</sup> | III, randomized | Second-line | Ramucirumab vs placebo       | OS                | HR: 1.27; 95% CI: 0.89–1.80; $P_{\text{trend}}$ |
| Cheng et al<sup>14</sup> | II, randomized | First-line | Dovitinib vs sorafenib       | OS                | HR: 0.63–1.76; $P_{\text{trend}}$ |
| Palmer et al<sup>13</sup> | II, randomized | First-line | Nintedanib vs sorafenib      | TTP               | HR: 0.84; (95% CI: 0.73, 0.98); $P=0.0219$ |
| Tabernero et al<sup>14</sup> | III, randomized | Second-line | FOLFIRI + ramucirumab         | OS                | HR: 0.58; $P=0.0034$       |
| Xu et al<sup>15</sup> | II, randomized | Refractory     | Faminitinib vs placebo       | PFS               |                            |

Notes: *A prespecified subgroup analysis according to baseline alpha-fetoprotein (AFP) level suggested that patients with baseline AFP ≥400 ng/mL might derive benefit from ramucirumab treatment vs placebo (OS HR: 0.67, 95% CI: 0.51–0.90; $P=0.0059$).

Abbreviations: CI, confidence interval; HR, hazard ratio; ns, nonsignificant; OS, median overall survival; PFS, progression-free survival; RR, response rate; TTP, time to progression.

Notable advances that may challenge the current paradigms in the management of rectal cancers are also presented. Results are summarized in Table 1.

**Steps ahead in upper gastrointestinal malignancies**

Recent advances in the understanding of gastric cancer biology and the comprehensive molecular analysis performed by the Cancer Genome Atlas (TCGA), which allowed recognizing four distinct disease subtypes, have served as the rationale for the development of novel targeted agents. Overexpression or amplification of the MET factor has been observed in gastric cancer and been correlated with unfavorable clinical outcomes. Compared to the proportion of genes identified by immunohistochemical (IHC) detection of overexpression, the rate of detection of activating mutations or amplifications of MET gene is higher, defining a small group of tumors with aggressive clinical behavior regardless of disease stage. AMG 337 is a highly selective, orally available MET inhibitor that showed promising preclinical activity. In a multicenter, Phase I, open-label trial, 80 patients with MET-amplified tumors and good performance status (PS) received increasing doses of AMG 337 monotherapy, defining 300 mg/day as the maximum tolerated dose. In the small subset of 13 heavily pretreated patients with MET-amplified gastroesophageal tumors exposed to AMG 337, the investigators observed a notable 62% rate of response. Interestingly, the response was fast and usually detectable within 4 weeks from treatment start, which may be a remarkable advantage for symptomatic patients. The experimental treatment had a favorable profile of tolerability. Dose-limiting toxicities were severe hypertension, headache, and increased amylase activity; the most common side effects were headache (45%), nausea (32%), vomiting (21%), fatigue (14%), and peripheral edema (12%); headache (9%) and fatigue (4.5%) were the most frequent severe adverse events.

Onartuzumab is a recombinant, fully humanized, monoclonal anti-MET antibody. Results of the randomized Phase II trial testing upfront FOLFOX6 with onartuzumab at the dose of 10 mg/kg or FOLFOX6 plus placebo were presented. One hundred and twenty-three patients with advanced gastroesophageal cancer were enrolled from 25 centers; key eligibility criteria included no previous treatments for metastatic disease, Eastern Cooperative Oncology Group (ECOG) PS status of 0 or 1, and retention of organ function. MET-positive patients, defined as those with ≥50% of tumor with moderate–strong intensity staining by centrally reviewed IHC, were well balanced in the two arms: 28% in the experimental arm vs 33% in the control arm. Stratification factors were histological subtype and previous gastrectomy. At data cutoff, 96 out of 121 randomized patients had progression-free survival (PFS) events, 74% of those exposed to FOLFOX and onartuzumab and 82% of those receiving FOLFOX and placebo. The primary end point, PFS, in the intention-to-treat population, was not met (6.77 months in the onartuzumab arm, 6.97 months in the placebo arm; hazard ratio [HR]: 1.08, 95% confidence interval [CI]: 0.71–1.63).

In addition, the preplanned analyses in the MET-positive population generated similarly disappointing results: median PFS was 5.95 months for those exposed to FOLFOX6 and onartuzumab vs 6.8 months for those treated with FOLFOX6 and placebo (HR: 1.38). No differences were found despite the use of different definitions for MET positivity.
The addition of onartuzumab was not beneficial, regardless of patients’ race, and produced more adverse events. It is unclear whether these negative results suggest a failure of the strategy or the unreliability of the current definition of MET positivity. In fact, while it is reasonable not to consider IHC MET overexpression a good driver for patient selection, it should also be recalled that a large Phase III trial testing onartuzumab was prematurely interrupted because of failure of the drug in lung cancers, and another randomized study testing rilotumumab in the advanced disease setting failed to meet the primary trial end point.

Targeting the immune checkpoints in solid malignancies is becoming a major methodological approach. T-lymphocytes may recognize and eliminate cancer antigens, while immune checkpoints such as cytotoxic T-lymphocyte-associated antigen (CTLA)-4 and programmed cell death (PD-1) receptor and its ligands (PD-L1, PD-L2) are able to suppress the activity of T-lymphocytes. Therefore, enhancing antitumor immunity by blocking PD-1 is now an attractive reality. Pembrolizumab, a highly selective IgG4k, humanized monoclonal antibody against PD-1, has recently received approval from the US Food and Drug Administration for the treatment of advanced melanoma after the failure of ipilimumab administration or BRAF V600E-mutant melanoma in progression following BRAF inhibitor administration. Because the high expression of PD-L1 on tumor gastric cells and macrophages can suppress immune surveillance and permit neoplastic growth, the molecule has become an interesting target even in gastric cancer. Preliminary data of the KEYNOTE-012 gastric cohort study, in which pembrolizumab (MK-3475) was given at 10 mg/kg every 2 weeks to 39 patients with PD-L1-positive advanced gastric cancer, were recently presented. The trial enrolled heavily pretreated Asian (19) or non-Asian (20) patients, wherein 67% received ≥2 treatment lines. Overall response rate (RR) was 30.8% (95% CI: 17.0–46.6) and 41% of patients experienced a decrease in tumor burden. Aim of the abstract was to analyze the relationship between PD-L1 expression level and clinical outcome in patients with advanced disease treated with pembrolizumab. Muro et al found a significant association between PD-L1 expression level and objective response rate (ORR; one-sided \( P=0.10 \)). Median overall survival (OS) was not reached, but the 6-month OS rate was surprisingly high (69%). Though described as easily manageable by the authors, the toxicity profile appears a bit challenging, with five severe adverse events (peripheral sensory neuropathy, fatigue, decreased appetite, hypoxia, and pneumonitis) and one drug-related death (hypoxia). Because the immune-related response may not be fully captured by conventional response criteria, it would be interesting to assess the response with immune-related response criteria to further confirm the activity of pembrolizumab. On the basis of the KEYNOTE results, a Phase III randomized trial that compares pembrolizumab to paclitaxel in patients with recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma who progressed after first-line treatment has been planned.

Perioperative chemotherapy is a standard of care in locally advanced gastroesophageal cancer in Europe. In the MAGIC population, the human epidermal growth factor receptor 2 (HER2) positivity was not a prognostic or predictive factor. In the NEOHX study, 36 patients with HER2-positive locally advanced gastric adenocarcinoma entered the Phase II trial to explore the combination of trastuzumab and chemotherapy in this setting. Patients were treated with three preoperative cycles of standard XELOX plus trastuzumab (loading dose 8 mg/kg, instead of 6 mg/kg), followed by definitive surgery. In the postoperative phase, patients received three other cycles of the same combination regimen and eventually 12 cycles of trastuzumab monotherapy. The primary end point of the study was 18 months disease-free survival (DFS). Median age at trial entry was 63 years. R0 resection was reached in 78% of the patients (three cases had a pathological complete response), median DFS rate at 18 months was 71%, 2-year OS rate was 75%, while median DFS and OS had not been reached. The trial results are very interesting in this biologically selected population and may promote the use of trastuzumab in resectable gastric cancer patients.

### Significant advances in HCC, pancreatic cancer, and ciliary tract adenocarcinoma

Ramucriumab is a humanized monoclonal antibody that specifically blocks the vascular endothelial growth factor receptor 2 (VEGFR2). The REACH trial is a randomized Phase III study investigating ramucirumab as a single agent for the treatment of advanced HCC after failure of first-line sorafenib. Unfortunately, the trial did not meet its primary end point. In fact, median OS was 9.2 months for ramucirumab vs 7.6 months for placebo. Interestingly the prespecified subgroup analysis suggested that baseline alpha-fetoprotein (AFP) level might be a predictive marker for ramucirumab efficacy. Among 250 patients with baseline AFP ≥400 ng/mL, OS HR was 0.67 (95% CI: 0.51–0.90;
drug-eluting beads transarterial chemoembolization. In the
95% CI: 0.52–1.47) (Table 1).

The treatment arms (11.9 months vs 11.4 months; HR: 0.88;
95% CI: 0.63–1.76). Accordingly, median OS was similar between
sorafenib (TTP: 5.5 months vs 3.8 months; HR: 1.05; 95%
CI: 0.89–1.80). Palmer et al
proposed a novel staging system for
advanced HCC patients receiving sorafenib. The authors
hypothesized that the antiangiogenic compound might induce
an inhibition of endothelial nitric oxide synthase (eNOS)
activity by blocking the VEGFRs, with a consequent decrease
of the production of nitric oxide, which is correlated with
tumor angiogenesis, invasion, and metastasis. On the basis
of this assumption, eNOS polymorphisms were retrospec-
tively investigated in 54 HCC patients receiving sorafenib.
Patiencing the b allele (five repetitions of 27 bp) of
eNOS were found to have improved OS. The variants 4aa
(four repeats of 27 bp in homozygosity), 4ab, and 4bb
were associated with a median OS of 5.7 months, 13.9 months,
and 23.6 months, respectively (P=0.016). For eNOS-786, the
presence of the T allele was associated with a statistically
significant, longer median OS (15.6 months vs 13.9 months,
respectively; P=0.031).

Two Phase II randomized studies with novel antitumor
agents were presented.24,25 Dovitinib was tested in patients
with advanced HCC in an attempt to overcome the fibroblast
growth factor receptors (FGFRs)-activated mechanism of
resistance, which is considered an escape pathway for
sorafenib activity. Nonetheless, dovitinib failed to prove
superior to sorafenib in the first-line treatment of HCC. In the
Phase II trial presented by Cheng et al24 OS was 34.6 weeks
for dovitinib and 36.7 weeks (23.3 weeks–49.3 weeks) for
sorafenib (HR: 1.27; 95% CI: 0.89–1.80). Palmer et al25
presented disappointing results for the triple angiokinase
inhibitor nintedanib. In a randomized Phase II trial, time
to progression (TTP) was similar between nintedanib and
sorafenib (TTP: 5.5 months vs 3.8 months; HR: 1.05; 95%
CI: 0.63–1.76). Accordingly, median OS was similar between
the treatment arms (11.9 months vs 11.4 months; HR: 0.88;
95% CI: 0.52–1.47) (Table 1).

Prajapati et al26 proposed a novel staging system for
patients with advanced HCC treated with doxorubicin
drug-eluting beads transarterial chemoembolization. In the
multivariate analysis, the independent factors for survival
were Child-Pugh class, ECOG PS, number of HCC lesions,
index HCC (iHCC) size, site of portal or hepatic venous
thrombosis, extrahepatic metastasis, and serum creatinine
and AFP levels. Consequentially, the Clinical, Imaging,
and Serum examination (CIS) staging system was proposed.
According to the study findings, patients were grouped into
different stages with different outcomes. The OS of stages I,
II, III, and IV was 40.4 months, 24 months, 10.6 months, and
2.6 months, respectively (P<0.0001).

A prognosis model was also suggested for patients with
locally advanced unresectable pancreatic cancer included
in the LAP 07 trial.27 In the multivariate analysis, the inde-
pendent factors for OS were age, pain, albumin levels, and
Response Evaluation Criteria in Solid Tumors (RECIST)
size. Three risk groups were identified: lower risk (n=17;
median OS: 18.8 months; group of reference); intermediate
risk (n=166; median OS: 13.4 months); higher risk (n=187;
median OS: 11.8 months). This easy-to-use prognostic model
might be relevant for treatment decision in clinical practice
and future trial design. Novel potential therapeutic options
for metastatic pancreatic cancer have been suggested from
analyses of randomized trials. In the three-arm NAPOLI-1
trial,28 417 patients who had failed a gemcitabine-based
first-line treatment were randomized to MM-398 (nanolipo-
somal encapsulation of irinotecan), 5-fluorouracil (FU) plus
leucovorin (LV), or a combination of MM-398 and 5FU/LV.
The primary end point of the trial was OS. The analysis in
the per-protocol population (patients who received at least
80% of the target dose in the first 6 weeks and did not violate
any inclusion/exclusion criteria) confirmed the favorable
OS, PFS, and ORR for the combination MM-398+5FU/LV
arm relative to the control 5FU/LV arm with a manage-
able safety profile, whereas single-agent MM-398 was not
superior to 5FU/LV.

A Phase I trial investigated the role of PF-04136309
(a novel C–C chemokine receptor type 2 inhibitor) in com-
bination with FOLFIRINOX for locally advanced pancreatic
cancer.29 Among 23 evaluable patients, 21 (91%) completed
all six cycles; 12 (52.2%) obtained a RECIST-defined
partial remission, whereas the remaining 11 (48%) had
stable disease. Curative resections were achieved in four
patients out of five with borderline resectable disease and
in two with locally advanced pancreatic cancer. Globally,
these very initial findings suggest that PF-04136309 and
MM-398+5FU/LV should undergo further investigation in
pancreatic cancer.
Relevant information about the genomic landscape of biliary tract cancer was derived from an analysis including >500 hundred patients. The primary aim of the study was to identify crucial molecular markers as potential candidates for targeted agents. Findings from this analysis showed that intrahepatic cholangiocarcinoma (IHCCA), extrahepatic cholangiocarcinoma (EHCCA) and gall bladder carcinoma (GBCA) share genomic alterations in cell cycle regulation (CDKN2B) and chromatin remodeling (ARID1A). IHCCA features FGFR fusions, isocitrate dehydrogenase (IDH)-1/2 substitutions, BRAF substitutions, and MET amplification, with a low KRAS-mutation frequency. EHCCA and GBCA feature ERBB2 amplifications (GBCA > EHCCA) and PIK3CA/MTOR pathway alterations. EHCCA has a high KRAS-mutation frequency, whereas the KRAS genomic alteration in GBCA is low. Knowledge of relevant genomic alterations will be a fundamental starting point in designing future clinical trials in this setting.

We believe that new data deriving from the 2015 Gastrointestinal Cancers Symposium on HCC, pancreatic cancer, and biliary tract cancer will serve as relevant integration to our scientific knowledge about this heterogeneous group of neoplasms. Although the search for novel therapeutic targets represents a priority in this setting, we should remember that an improvement in the use of already available treatment options is equally important. Recent presentation of results from an analysis of polymorphisms in the angiogenic pathway of HCC patients receiving sorafenib should be integrated with already known data in this area and with clinical data defining prognostic groups. Similar considerations are applicable to data presented on patients with pancreatic cancer and biliary tract cancer.

**Colorectal cancers: integrating novel drugs in innovative strategies**

Results of the treatment with new antiangiogenic agents have been reported. Two studies suggested that ramucirumab and famitinib might soon be added to the armamentarium for metastatic CRC. The RAISE trial demonstrated that the addition of ramucirumab to second-line FOLFIRI chemotherapy resulted in a significant delay in disease progression and prolongation of survival in patients with metastatic CRC who had previously failed a first-line chemotherapy containing bevacizumab. The primary end point was OS. Ramucirumab reduced the risk for death by 16% (HR: 0.84; P=0.0219) and prolonged survival by a median of 1.6 months compared with FOLFIRI alone (median OS: 13.3 months vs 11.7 months). In addition, ramucirumab reduced the risk of disease progression by 21% (HR: 0.79; P=0.0005).

The efficacy and safety of famitinib, a small multi-target receptor tyrosine kinase inhibitor, which primarily inhibits VEGFR2, cKit, and PDGFR, were evaluated in a multicenter, randomized, double-blind, Phase II trial. The study included 154 advanced CRC patients, who were randomly assigned in a 2:1 ratio to receive either famitinib or placebo. All patients had previously failed at least two lines of standard therapy. The primary end point was PFS. Famitinib increased median PFS from 1.5 months to 2.8 months (HR: 0.58; 95% CI: 0.41–0.86; P=0.0034). No statistical difference was observed in median OS with famitinib vs placebo (7.5 months vs 7.6 months; HR: 1.10; 95% CI: 0.76–1.60; P=0.605). The safety profile of famitinib was similar to that of other anti-VEGFR agents. Although these studies indicate that there will be alternative treatment options for metastatic CRC in the near future, they represent confirmations of the previously consolidated strategy of chemotherapy and antiangiogenic agent combination in unselected patients. During this edition of the conference, a significant convergence was also demonstrated in refining molecular selection to increase the effectiveness of targeted therapies and particularly in developing a “beyond-RAS” strategy, many works from all over the world have explored new screening, predictive biomarkers, and targeted therapies for metastatic CRC patients.

Preliminary data from two multinational screening platforms show that collaborative genomic analysis beyond the RAS is feasible and might be used to run next-generation trials with targeted agents. The European Organisation for Research and Treatment of Cancer (EORTC) Screening Patients for Efficient Clinical Trial Access in advanced colorectal cancer (SPECTAcolor), a pan-European network, has already analyzed 406 patients in the first year and has planned to use next-generation sequencing for 360 key cancer alterations. A nationwide genomic screening project in Japan has evaluated a total of 361 tumor samples in the first 6 months to detect rare mutations such as PI3KCA and BRAF mutations.
Some other studies have shown that a strategy “from bench to bedside” is being pursued. The combination of the EGFR inhibitor panitumumab with the BRAF inhibitor vemurafenib for \(BRAF\)-mutant metastatic CRC has shown interesting hints of activity.\(^{40}\) Two of 12 evaluable patients (13%) had confirmed long-lasting partial responses, whereas 8 patients (53%) had stable disease. The combination was well tolerated, with acniform rash, fatigue, and arthralgia being the most frequent treatment-related adverse events. On the basis of the same assumption that activation of the EGFR pathway is the leading cause of failure of anti-\(BRAF\) monotherapy, a randomized Phase II trial of irinotecan plus cetuximab with or without vemurafenib is also currently ongoing.\(^{31}\)

Because another mechanism of resistance to anti-EGFR therapy is supposed to be HER2 amplification, in the Italian study HERACLES, heavily pretreated patients with HER2-positive, EGFR inhibitor-refractory advanced CRC have been treated with the combination of lapatinib and trastuzumab.\(^{42}\)

As expected from the literature,\(^{43}\) the screening failure for HER2-positive patients was impressively high. Eighteen patients were enrolled (2.8% of the patients screened), and an ORR of 33% was achieved. Patients with HER2 3+ CRC and with a gene copy number \(\geq 20\) had the highest chance to respond to the dual inhibition.

Besides the new therapies and new strategies, the 2015 Gastrointestinal Cancers Symposium challenged some old paradigms. A retrospective review of 145 patients with locally advanced rectal cancer who received standard neoadjuvant chemoradiation suggests that patients who obtained a clinical complete response can avoid surgery with little compromise in the overall outcomes.\(^{44}\) After a median follow-up of 3.5 years, there were no significant differences in disease-specific parameters or OS between patients who had a clinical complete response to preoperative therapy and skipped surgery on the one hand and patients who underwent rectal resection with a pathologic complete response (pCR) on the other. The study highlighted that a nonoperative approach may obtain preservation of rectal function in more than three-fourths of the patients.

The optimal timing of surgical resection of rectal cancer after preoperative chemoradiation was investigated in a retrospective analysis of 6,805 patients in the National Cancer Database.\(^{45}\) A significant relationship between time delay (TD) and pCR was demonstrated \((P=0.0002)\). At TD \(<30\) days, 4.0% of patients achieved pCR, while 9.3% of patients achieved pCR by 75 days. At TD \(>75\) days, the rate of pCR decreased. However, TD of \(>60\) days was associated with 20% greater risk of mortality (95% CI: 1.07–1.36). Direct correlation between pCR and survival does not seem very strong in rectal cancer.

**Conclusion**

In the era of targeted therapies, trastuzumab and ramucirumab are the only biologic therapy agents approved for patients with advanced gastroesophageal cancers, the first being limited for use in the 15% of patients with HER2-positive tumors. There is a need for novel agents to be offered to these patients. In this landscape, MET inhibitors fostered the debate, with discordant results: while onartuzumab and rilotumumab did not fulfill their promises, AMG 337 provided interesting results. After several years of intense clinical and translational research, sorafenib still remains the only available therapeutic option for patients with advanced HCC. However, novel prognostic markers and interesting treatment strategies might, in the near future, change the way we approach this highly deadly disease. Besides TH-302, other novel drugs have emerged against pancreatic cancers.

MM-398, an investigational nanocompound consisting of the chemotherapeutic irinotecan encapsulated in a liposomal sphere, and PF-04136309, a novel orally available human chemokine receptor 2 antagonist with immunomodulating and antineoplastic properties, may provide new hope for patients with advanced disease when combined with standard chemotherapy. With the expansion of the process of knowledge acquisition on CRC biology and, correspondingly, of growth of complexity, famitinib and ramucirumab will provide new options to patients with advanced disease. Once again, many studies have been presented. Hopefully, the time needed to transfer these scientific advances to clinical practice will be shorter than ever.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Mayer RJ, Venook AP, Schilsky RL. Progress against GI cancer during the American Society of Clinical Oncology’s first 50 years. *J Clin Oncol*. 2014;32(15):1521–1530.

2. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. *Nature*. 2014;513(7517):202–209.

3. Aprile G, Giampieri R, Bonotto M, et al. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. *Expert Opin Investig Drugs*. 2014;23(7):925–942.

4. An X, Wang F, Shao Q, et al. MET amplification is not rare and predicts unfavorable clinical outcomes in patients with recurrent/metastatic gastric cancer after chemotherapy. *Cancer*. 2014;120(5):675–682.

5. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagegastric adenocarcinoma with evidence of responsiveness to crizotinib. *J Clin Oncol*. 2011;29(36):4803–4810.
6. Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011;29(36):4789–4795.

7. Kwak EL, LoRusso P, Hamid O, et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. J Clin Oncol. 2015;33(suppl 3; abstr 1).

8. Shah MA, Cho JY, Huat IT, et al. Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O); in advanced gastroesophageal adenocarcinoma (GEC). J Clin Oncol. 2015;33(suppl 3; abstr 2).

9. Available from: http://www.roche.com/media/store/releases/med-cor-2014-03-03.htm. Accessed on February 8th 2015.

10. Available from: http://www.prnewswire.com/news-releases/amgen-announces-termination-of-all-amgen-sponsored-clinical-studies-of-rirotumumab-in-advanced-gastric-cancer-300000103.html. Accessed on February 8th 2015.

11. Hersey P, Gownshankar K. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncol. 2015;11(1):133–140.

12. Sun J, Xu K, Wu C, et al. PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. Tissue Antigens. 2007;69(1):19–27.

13. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.

14. Muro K, Bang Y, Shankaran V, et al. A phase 1B study of pembrolizumab (PEMBRO; MK-3475) in patients (PTS) with advanced gastric cancer. Ann Oncol. 2014;25(suppl 5):v1–v41.

15. Muro K, Bang YJ, Shankaran V, et al. Relationship between PD-L1 clinical and outcomes in patients (Ps) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. J Clin Oncol. 2015;33(suppl 3; abstr 3).

16. Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7474.

17. Cunningham D, Allum WH, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

18. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–1721.

19. Okines AF, Thompson LC, Cunningham D, et al. Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Ann Oncol. 2013;24(5):1253–1261.

20. Rivera F, Jimenez-Fonseca P, Garcia Alfonso P, et al. NEOHX study: multivariate survival analysis of the patients with unresectable metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(suppl 3; abstr 611).

21. Aprile G, Rijavec E, Fontanella C, Rihawi K, Grossi F. Ramucirumab: a pan-metastatic therapeutic option in gastroenterological oncology. J Clin Oncol. 2015;33(suppl 3; abstr 236).

22. Verneyre D, Hammel P, Paget-Bailly S, et al. Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: an ancillary study of the LAP 07 trial. J Clin Oncol. 2015;33(suppl 3; abstr 235).

23. Chen LT, Von HoFF DD, Pin Li C, et al. Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy. J Clin Oncol. 2015;33(suppl 3; abstr 234).

24. Wang-Gillam A, Nyvening TM, Sanford DM, et al. Phase IB study of FOLFIRINOX plus PF-04136309 in patients with borderline resectable and locally advanced pancreatic adenocarcinoma (PC). J Clin Oncol. 2015;33(suppl 3; abstr 338).

25. Ross JS, Wang K, Catenacci DVT, et al. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and genomic alterations. J Clin Oncol. 2015;33(suppl 3; abstr 231).

26. Tabernero J, Cohn AL, Obermannova R, et al. RAISE: a randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (oxa), and a fluoropyrimidine (fp). J Clin Oncol. 2015;33(suppl 3; abstr 512).

27. Xu R, Shen L, Wang K, et al. A randomized, double-blind, parallel-group, placebo-controlled, multicenter, phase II clinical study of farnitinib in the treatment of advanced metastatic colorectal cancer. J Clin Oncol. 2015;33(suppl 3; abstr 513).

28. Apriie G, Luturino SE, Ferrari L, et al. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol. 2013;19(46):8474–8488.

29. Giampieri R, Aprile G, Del Prete M, et al. Beyond RAS: the role of epidermal growth factor receptor (EGFR) and its network in the prediction of clinical outcome during anti-EGFR therapy in colorectal cancer patients. Curr Drug Targets. 2014;15(13):1225–1230.

30. Holprech R, Gütte A, Roth A, et al. Improving access to molecularly defined clinical trials for patients with colorectal cancer: the EORTC SPECTAcolor platform. J Clin Oncol. 2015;33(suppl 3; abstr 575).

31. Shitara K, Fujii S, Denda T, et al. The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01). J Clin Oncol. 2015;33(suppl 3; abstr 578).

32. Yang J, Reitze H, Straathof P, et al. Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. J Clin Oncol. 2015;33(suppl 3; abstr 611).

33. Yang J, Reitze H, Straathof P, et al. S1406: randomized phase II study of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(suppl 3; abstr TPS790).
42. Siena S, Sartore-Bianchi A, Trusolino L, et al. Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): the HERACLES trial. *J Clin Oncol*. 2015;33(suppl 3; abstr 565).

43. Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. *Br J Cancer*. 2014;111(10):1977–1984.

44. Smith JJ, Chow OS, Eaton A, et al. Organ preservation in patients with rectal cancer with clinical complete response after neoadjuvant therapy. *J Clin Oncol*. 2015;33(suppl 3; abstr 509).

45. Huntington CH, Boselli D, Hill JS, Jonathan C. Optimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: an analysis of the National Cancer Database (NCDB). *J Clin Oncol*. 2015;33(suppl 3; abstr 510).